Clinical observation of the efficacy of flupentixol and melitracen in the treatment of functional dyspepsia with anxiety and depression symptoms
氟哌噻吨美利曲辛治疗伴有焦虑抑郁症状的功能性消化不良的疗效观察

摘要

目的 探讨氟哌噻吨美利曲辛在功能性消化不良伴焦虑抑郁症状患者中的临床疗效，评估其对消化道症状缓解及情绪改善的综合作用。方法 于2021年5月至2025年5月期间，连续纳入符合诊断标准的功能性消化不良伴焦虑抑郁症状患者共80例，随机分为对照组与实验组，各40例。对照组接受常规消化系统对症治疗，实验组在此基础上加用氟哌噻吨美利曲辛片。采用胃肠症状评分量表、汉密尔顿焦虑量表及汉密尔顿抑郁量表进行疗效评价，同时记录不良反应情况，比较两组在治疗后症状缓解程度及精神心理状态改善情况。结果 实验组在胃部不适、饱胀、嗳气等消化道症状改善方面优于对照组，焦虑及抑郁评分下降幅度更显著，整体临床有效率较高。实验组在依从性方面表现更佳，患者日常生活质量提升幅度更为明显，不良反应发生率低且耐受性良好。结论 氟哌噻吨美利曲辛在功能性消化不良伴焦虑抑郁症状患者中可有效缓解消化道症状，改善焦虑与抑郁状态，具有较高临床应用价值，提示其在身心共病治疗中的优势地位。

Abstract

Objective To investigate the clinical efficacy of flupentixol and melitracen in patients with functional dyspepsia accompanied by anxiety and depressive symptoms, and to evaluate its comprehensive effects on gastrointestinal symptom relief and emotional improvement.
Methods From May 2021 to May 2025, a total of 80 patients meeting the diagnostic criteria for functional dyspepsia with anxiety and depressive symptoms were consecutively enrolled and randomly divided into a control group and an experimental group, with 40 cases in each. The control group received conventional symptomatic treatment for the digestive system, while the experimental group additionally received flupentixol and melitracen tablets. The Gastrointestinal Symptom Rating Scale (GSRS), Hamilton Anxiety Scale (HAMA), and Hamilton Depression Scale (HAMD) were used to evaluate efficacy. Adverse reactions were recorded, and the degree of gastrointestinal symptom relief and psychological improvement after treatment was compared between groups.
Results The experimental group showed more significant improvement in gastrointestinal symptoms such as epigastric discomfort, bloating, and belching compared with the control group. The reductions in anxiety and depression scores were more pronounced, and the overall clinical efficacy rate was higher. The experimental group also demonstrated better treatment compliance, greater improvements in daily quality of life, and lower incidence of adverse reactions with good tolerability.
Conclusion   Flupentixol and melitracen can effectively relieve gastrointestinal symptoms and improve anxiety and depressive states in patients with functional dyspepsia, with high clinical application value, highlighting its advantages in the management of comorbid somatic and psychological conditions.